14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs OSUR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas OSUR carries 56.9/100 (HOLD) at $3.60 (40.0x Forward P/E, -58.2% operating margin).
Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRA vs OSUR. Trailing 12-month operating profitability (BMRA -125.2% vs OSUR -58.2%) and valuation multiples (BMRA N/M vs OSUR 40.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $250.0M market capitalization and -58.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BMRA vs OSUR Key Questions & Quantitative Answers
As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas OSUR carries 56.9/100 (HOLD) at $3.60 (40.0x Forward P/E, -58.2% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OSUR leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with OSUR at +14.1% YoY revenue growth and +29.6% YoY earnings growth on $116M TTM revenue (43.1% gross margin, -58.2% operating margin). On trailing 12-month operating scale, BMRA generates $4.3M in USD-normalized revenue versus $116M for OSUR. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OSUR.
OSUR screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas OSUR trades at 40.0x Forward P/E, 40.0x Trailing P/E, 6.19x PEG, and 2.2x EV/Revenue (-50.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus OSUR (-14.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, OSUR carries 47.6% implied volatility (77th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.25β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.